<DOC>
	<DOCNO>NCT00872482</DOCNO>
	<brief_summary>This randomize , Phase II study design investigate Nimotuzumab plus whole-brain radiation therapy ( WBRT ) compare rith WBRT alone patient brain metastases non-small cell lung cancer ( NSCLC ) . The purpose study assess efficacy nimotuzumab combination WBRT .</brief_summary>
	<brief_title>A Study Nimotuzumab Combination With Radiation Therapy Patients With Brain Metastases</brief_title>
	<detailed_description>A phase II , randomize , control , double blind multicenter study 2 arm , administer study drug radiotherapy follow radiotherapy disease progression , unacceptable toxicity discretion physician . Randomization do 2:1 ( experimental : control ) . Chemotherapy add documented disease progression discretion physician . The primary objective ass efficacy Nimotuzumab combination WBRT . The primary endpoint intracranial disease progression 6 month . The secondary endpoint overall survival ( OS ) ; time neurologic progression ( TNP ) death evidence neurologic progression ; OS rate 6 month ; time intracranial disease progression ; time overall progression . Tissue sample serum collect future correlative study . All image centrally review end study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>Providing write informed consent ( see Appendix A ) ; Age ≥18 year ; Histologic cytologic confirm diagnosis NSCLC epithelial type ( squamous , adenocarcinoma , large cell , ) ; At least one newly diagnose measurable metastatic lesion NSCLC brain ; Patient initial diagnosis brain metastasis image , within 8 week registration KPS ≥70 ; Absolute neutrophil count ≥ 1500/mm³ ; Platelet count ≥ 50,000/mm³ ; Serum creatinine ≤2.0 mg/dL ; Serum transaminases ≤2 x upper limit normal ( ULN ) ; Total serum bilirubin ≤2 x ULN ; And lactate dehydrogenase ( LDH ) level ≤1.3 x ULN . Pregnancy , lactation parturition within previous 30 day ( fertile female male patient practice contraception ) ; Prior WBRT , brain metastasis resection measurable lesion remain ; Extracranial metastasis two organ ; Known leptomeningeal subarachnoid tumor spread ; Plan use radiosurgery radiation boost completion WBRT ; Plan use chemotherapy systemic antineoplastic modality WBRT ; Previous use antiEGFR drug ; Participation another ongoing therapeutic trial ; Presence know HIV seropositivity , severe comorbidities , malignant neoplasm within 5 year ( except adequately treat basal squamouscell carcinoma skin situ carcinoma uterine cervix ) ; Hypersensitivity allergy drug administer study ; Inability unwillingness complete require assessment ; Geographic inaccessibility treatment followup evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Brain metastasis</keyword>
	<keyword>nimotuzumab</keyword>
	<keyword>TheraCIM</keyword>
	<keyword>h-R3</keyword>
	<keyword>Radiation</keyword>
</DOC>